An additional $420M is dependent on attaining development milestones of this early-stage candidate.

Amgen will receive an exclusive license for Kyowa Hakko Kogyo’s mAb for inflammation and oncology indications in a deal worth $520 million. Amgen will pay $100 million upfrom for the worldwide development and commercialization rights to the compound.  Kyowa Hakko, however, retains rights in  Japan, Korea, China, and Taiwan.


Kyowa Hakko could receive up to $420 million in development, approval, and sales milestones. The company is also entitled to receive double-digit royalties.


Kyowa Hakko has completed Phase I studies of KW-0761 in allergic rhinitis. Phase I trials in lymphoma patients is ongoing. Amgen will initially acquire rights in all nononcology indications, and Kyowa Hakko will continue its development activities in oncology until the completion of Phase IIa. At that time, Amgen may elect to reimburse Kyowa Hakko for its oncology-related development costs, expand its license to include oncology.

Previous articleScientists Discover that Certain Epigenetic Changes Are Only Temporary
Next articleResearchers Develop New Model for Predicting 3-D Structure of RNA